14 studies on FOXO4-DRI curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This study highlights FOXO4-D-Retro-Inverso as a promising novel therapeutic agent for pulmonary fibrosis by directly targeting the underlying mechanism of excessive extracellular matrix production by fibroblasts. The…
This study provides compelling evidence that Longevity-Max, a specific CHM blend, can modulate fundamental molecular pathways associated with aging, including telomere maintenance, sirtuin activation, and inflammation…
This detailed structural characterization provides a fundamental understanding of how FOXO4-DRI exerts its senolytic effects, by directly targeting and modulating the p53 pathway through a unique transient binding mec…
This research is highly significant as it identifies a novel and effective therapeutic strategy for combating age-related diseases and potentially extending healthy lifespan. By specifically targeting the FOXO4-p53 in…
This study provides compelling evidence that targeting cellular senescence with Fisetin can effectively mitigate and even reverse age-related and disease-induced kidney dysfunction. The ability to significantly improv…
These findings are highly significant as they reveal a novel mechanism for age-related testosterone insufficiency and offer a targeted therapeutic strategy. The ability of FOXO4-DRI to selectively induce apoptosis in …
This research highlights the therapeutic potential of senolytic peptides like FOXO4-DRI in targeting and removing harmful senescent cells from cartilage. By selectively eliminating these dysfunctional cells, FOXO4-DRI…
This research highlights the FOXO4 peptide as a promising novel therapeutic candidate for pulmonary fibrosis, offering a targeted approach by suppressing myofibroblast activation and disrupting detrimental ECM-recepto…
This research highlights FOXO4-DRI as a promising therapeutic agent for combating age-related male infertility by specifically targeting and eliminating senescent Leydig cells. By blocking the FOXO4-p53 interaction, t…
This research highlights a novel therapeutic strategy for keloids by precisely targeting senescent fibroblasts and their inherent resistance to apoptosis. By modulating p53 activity and promoting its nuclear exclusion…
This research highlights FOXO4-DRI as a potent anti-senolytic agent, capable of rejuvenating endothelial cells and improving vascular health by modulating the P53 pathway. The ability to reverse cellular aging in the …
This study provides compelling evidence that FOXO4-DRI effectively clears senescent cells and mitigates multiple hallmarks of aging in a preclinical model. The observed improvements in physical function and metabolic …
Free, no account — handy when you're working with FOXO4-DRI.